Hamburg, Germany - 26 April 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB (NASDAQ OMX: ACTI), to further advance an existing programme, which has entered the lead optimisation phase. The programme aims to find novel small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.
The programme was initiated in 2010 with a high throughput screen followed by extensive hit validation and hit-to-lead activities, leveraging Evotec's hit identification and integrated medicinal chemistry platforms.
Dr Mario Polywka, Chief Operating Officer at Evotec stated: "We are delighted that our already successful collaboration with Active Biotech has been extended and expanded with the aim of taking this exciting programme through lead optimisation towards candidate nomination. This is an area where Evotec has a significant track record of success and we look forward to leveraging our expertise to assist Active Biotech in finding novel treatments addressing cancer and autoimmune disorders."
Dorthe da Graça Thrige, Director of Development of Active Biotech, commented: "Active Biotech strives to develop, efficiently and cost-effectively, new remedies for illnesses where today's treatment options are inadequate, especially in the area of cancer and autoimmune diseases. It is key for us to collaborate with first class companies and we have been very impressed with Evotec's hit identification and subsequent hit to lead activities on this important target and now look forward to progressing the leads through to candidate drug selection."
No financial details are disclosed.